亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

医学 多发性骨髓瘤 耐火材料(行星科学) 打开标签 内科学 来那度胺 临床研究阶段 肿瘤科 临床试验 天体生物学 物理
作者
Ajai Chari,Cyrille Touzeau,Carolina Schinke,Monique C. Minnema,Jesús G. Berdeja,Albert Oriol,Niels W.C.J. van de Donk,Paula Rodríguez‐Otero,Daniel Morillo,Carmen Martínez‐Chamorro,María‐Victoria Mateos,Luciano J. Costa,Jo Caers,Leo Rasche,Amrita Krishnan,Jing Christine Ye,Lionel Karlin,Brea C. Lipe,Deeksha Vishwamitra,Sheri Skerget
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:12 (4): e269-e281 被引量:110
标识
DOI:10.1016/s2352-3026(24)00385-5
摘要

BACKGROUND: Talquetamab is the first GPRC5D × CD3 bispecific antibody approved for relapsed or refractory multiple myeloma. In phase 1 of the MonumenTAL-1 study, initial results of subcutaneous talquetamab 0·4 mg/kg once a week and 0·8 mg/kg every 2 weeks showed preliminary clinical activity. We describe safety and activity results in patients treated with talquetamab, including patients who had received previous T-cell redirection therapy (TCR). This post-hoc analysis was done with more mature median follow-up to evaluate duration of response in patients treated with talquetamab 0·8 mg/kg every 2 weeks. METHODS: MonumenTAL-1 is a multicentre, open-label, phase 1-2 study of talquetamab, phase 1 of which has previously been published. The 0·4 mg/kg once a week and 0·8 mg/kg every 2 weeks recommended subcutaneous doses identified in phase 1 were evaluated in phase 2 in patients who were 18 years of age or older, had at least three previous lines of therapy, had an Eastern Cooperative Oncology Group performance status of 0 to 2, and were naive or exposed to previous TCR. The primary endpoint was overall response rate assessed by independent review committee in all patients who received at least one dose of talquetamab. Safety was assessed in all patients who received at least one dose of talquetamab. This study was registered with ClinicalTrials.gov, NCT03399799 (phase 1) and NCT04634552 (phase 2). FINDINGS: Between Jan 3, 2018, and Feb 20, 2023, 735 patients were screened across all phase 1-2 cohorts. Of these, 537 patients screened for inclusion were treated across phase 1 and 2 cohorts, of whom 198 (27%) patients were excluded from the study, most commonly due to not meeting eligibility criteria or not having measurable disease. As of Oct 11, 2023, 375 patients had received recommended talquetamab doses across three groups: 143 (0·4 mg/kg once a week group) and 154 (0·8 mg/kg every 2 weeks group) TCR-naive patients and 78 with previous TCR who received either recommended dose (previous TCR group). 217 (58%) of 375 patients were male and 158 (42%) were female. 325 (87%) of 375 patients were White and 32 (9%) patients were Black. Median follow-up was 25·6 months (IQR 8·5-25·9) in the 0·4 mg/kg once a week group, 19·4 months (9·2-20·7) in the 0·8 mg/kg every 2 weeks group, and 16·8 months (7·6-18·7) in the previous TCR group. Overall response rate was 74% (106 of 143 patients, 95% CI 66-81) in the 0·4 mg/kg once a week group, 69% (107 of 154 patients, 62-77) in the 0·8 mg/kg every 2 weeks group, and 67% (52 of 78 patients, 55-77) in the previous TCR group. Most common adverse events in the 0·4 mg/kg once a week, 0·8 mg/kg every 2 weeks, and previous TCR groups were cytokine release syndrome (113 [79%] of 143 patients, 115 [75%] of 154 patients, and 57 [73%] of 78 patients), taste changes (103 [72%], 110 [71%], and 59 [76%]), and infections (85 [59%], 105 [68%], and 59 [76%]). Most common grade 3-4 adverse events were neutropenia (44 [31%], 33 [21%], and 37 [47%]), anaemia (45 [31%], 40 [26%], and 21 [27%]), and lymphopenia (37 [26%], 40 [26%], and 13 [17%]). Fatal adverse events occurred in five patients in the 0·4 mg/kg once a week group, seven patients in the 0·8 mg/kg every 2 weeks group, and no patients in the previous TCR group; none were related to treatment. INTERPRETATION: Talquetamab continued to demonstrate high overall response rates in heavily pretreated patients with relapsed or refractory multiple myeloma with longer follow-up in this post-hoc analysis. Overall response rate was promising in patients with previous TCR, including therapies targeting BCMA. On-target, off-tumour adverse events were common but led to few treatment discontinuations. FUNDING: Janssen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
万能图书馆的应助被吐司采纳,获得10
6秒前
海洋球发布了新的文献求助10
7秒前
dolabmu完成签到 ,获得积分10
9秒前
魔幻雅柔完成签到,获得积分10
10秒前
月亮打烊完成签到 ,获得积分10
13秒前
文静楷瑞完成签到,获得积分10
16秒前
fx完成签到 ,获得积分10
18秒前
18秒前
fantasy的应助被十三采纳,获得10
19秒前
深情安青的应助被outlast采纳,获得10
24秒前
十三完成签到,获得积分10
25秒前
26秒前
30秒前
拼搏问薇完成签到 ,获得积分10
31秒前
32秒前
Abcqqq完成签到 ,获得积分10
32秒前
海洋球完成签到,获得积分10
34秒前
ll完成签到,获得积分20
34秒前
小蘑菇的应助被xx2026采纳,获得10
35秒前
36秒前
kxz完成签到 ,获得积分10
36秒前
37秒前
gale发布了新的文献求助10
40秒前
红墨发布了新的文献求助30
41秒前
43秒前
怕黑的驳完成签到,获得积分10
44秒前
46秒前
47秒前
48秒前
49秒前
吐司发布了新的文献求助10
50秒前
冷静新烟完成签到,获得积分10
50秒前
gale完成签到,获得积分10
53秒前
58秒前
58秒前
TIDUS完成签到,获得积分10
1分钟前
独特的念柏完成签到,获得积分10
1分钟前
sadascaqwqw发布了新的文献求助10
1分钟前
36hours完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195004
求助须知:如何正确求助?哪些是违规求助? 9580729
关于积分的说明 21872554
捐赠科研通 7794720
什么是DOI,文献DOI怎么找? 3437836
关于科研通互助平台的介绍 2561159
邀请新用户注册赠送积分活动 2484541